---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-033574"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2022-02-10T23:59:59+00:00"
generated_at: "2026-06-27T09:16:14.324566+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AlloVir reports FY2021 net loss $172M; cash $248.1M; three Phase 3 trials advancing

## Summary
- Net loss $172.0M ($2.74/share) for 2021 vs. $69.8M in 2020; cash $248.1M at year-end.
- Three Phase 3 registrational studies of posoleucel: HC, AdV treatment enrolling; multi-virus prevention expected 1H22.
- R&D expenses $120.7M in 2021; 2022 operating expense guidance $130-145M (excl. stock comp).
- ALVR106 Phase 1/2 for respiratory viruses initiated Dec 2021; ALVR107 preclinical for hepatitis B ongoing.
- Initial data from posoleucel BK viremia POC study in kidney transplant expected 1H22.

## SEC filing metadata
- accession: 0001193125-22-033574
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2022-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312522033574/0001193125-22-033574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312522033574/d196801d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-033574
- JSON: https://secwatch.observer/filing/0001193125-22-033574.json
- Plain text: https://secwatch.observer/filing/0001193125-22-033574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.